Literature DB >> 11110671

I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo.

G Bernardini1, G Spinetti, D Ribatti, G Camarda, L Morbidelli, M Ziche, A Santoni, M C Capogrossi, M Napolitano.   

Abstract

Several chemokines have been shown to act as angiogenic molecules or to modulate the activity of growth factors such as fibroblast growth factor 2 (FGF-2) and vascular endothelial growth factor (VEGF). The detection of the CC chemokine receptor (CCR) 8 message in human umbilical vein endothelial cells (HUVECs) by reverse transcription- polymerase chain reaction (RT-PCR) and RNase protection assay (RPA), prompted us to investigate the potential role exerted by the CC chemokine I-309, a known ligand of such receptor, in both in vitro and in vivo angiogenesis assays. We show here that I-309 binds to endothelial cells, stimulates chemotaxis and invasion of these cells, and enhances HUVEC differentiation into capillary-like structures in an in vitro Matrigel assay. Furthermore, I-309 is an inducer of angiogenesis in vivo in both the rabbit cornea and the chick chorioallantoic membrane assay (CAM).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110671

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array.

Authors:  Ana Abajo; Nerea Bitarte; Ruth Zarate; Valentina Boni; Ines Lopez; Marisol Gonzalez-Huarriz; Javier Rodriguez; Eva Bandres; Jesus Garcia-Foncillas
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

2.  In vitro imaging of single living human umbilical vein endothelial cells with a clinical 3.0-T MRI scanner.

Authors:  Z Zhang; E J van den Bos; P A Wielopolski; M de Jong-Popijus; M R Bernsen; D J Duncker; G P Krestin
Journal:  MAGMA       Date:  2005-08-10       Impact factor: 2.310

3.  Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy.

Authors:  Yan Zheng; Yuanyuan Zha; Robbert M Spaapen; Rebecca Mathew; Kenneth Barr; Albert Bendelac; Thomas F Gajewski
Journal:  Mol Immunol       Date:  2013-03-30       Impact factor: 4.407

Review 4.  Clinical utilization of chemokines to combat cancer: the double-edged sword.

Authors:  Chiara Dell'Agnola; Arya Biragyn
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

5.  Compatibility of superparamagnetic iron oxide nanoparticle labeling for ¹H MRI cell tracking with ³¹P MRS for bioenergetic measurements.

Authors:  Zhuoli Zhang; Brynne Hancock; Stephanie Leen; Sharan Ramaswamy; Steven J Sollott; Kenneth R Boheler; Magdalena Juhaszova; Edward G Lakatta; Richard G Spencer; Kenneth W Fishbein
Journal:  NMR Biomed       Date:  2010-09-20       Impact factor: 4.044

6.  CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-β1.

Authors:  Giuseppe Sciumè; Alessandra Soriani; Mario Piccoli; Luigi Frati; Angela Santoni; Giovanni Bernardini
Journal:  Neuro Oncol       Date:  2010-02-08       Impact factor: 12.300

Review 7.  Senescent cells as a source of inflammatory factors for tumor progression.

Authors:  Albert R Davalos; Jean-Philippe Coppe; Judith Campisi; Pierre-Yves Desprez
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

8.  Autocrine and paracrine promotion of cell survival and virus replication by human herpesvirus 8 chemokines.

Authors:  Young Bong Choi; John Nicholas
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

Review 9.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

Review 10.  Role of chemokines in tumor growth.

Authors:  Dayanidhi Raman; Paige J Baugher; Yee Mon Thu; Ann Richmond
Journal:  Cancer Lett       Date:  2007-07-12       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.